{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:18:39Z","timestamp":1777965519516,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We investigated the impact of prostate-specific membrane antigen (PSMA) PET\/CT compared with conventional imaging on treatment outcomes for node-positive prostate cancer (PCa) patients who underwent androgen deprivation therapy (ADT) and external radiotherapy (RT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>A multicentric, retrospective study recruited patients with node-positive PCa patients who underwent conventional radiological evaluation or PSMA PET\/CT and received ADT and RT at 3 hospitals from 2009 to 2021 were enrolled. Patients underwent prostate and pelvis RT, accompanied by a minimum of 6 months of ADT. The primary endpoints were progression-free survival (PFS) and PCa-specific survival (PCSS). Cox regression analyzed the association of survival with potential prognostic factors, whereas logistic regression identified the predictors of bone and lymph node metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median follow-up time was 64.0 months. The majority of patients (64.1%) underwent PSMA PET\/CT for staging. The 5-year rates of PFS and PCSS were 63.7% and 83.7%, respectively. Disease progression was observed in 90 patients (36.3%). In multivariable analysis, ADT duration of less than 24 months and post-RT prostate-specific antigen (PSA) nadir were prognostic for PFS. Early clinical T stage and PSMA PET\/CT predicted better PCSS. Patients staged with PSMA PET\/CT had exhibited significantly higher 5-year PCSS rates than compared with those staged with conventional imaging (95.1% vs 76.9%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01). Shorter ADT duration and higher PSA levels after RT independently predicted bone metastasis in multivariable logistic regression. Advanced T stage, shorter ADT duration, and higher PSA levels after neoadjuvant ADT predicted nonregional lymph node recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>ADT with pelvis RT is an effective treatment option for node-positive PCa patients. The PSMA PET\/CT outperformed conventional imaging in PCSS, emphasizing the importance of precise clinical staging for patients undergoing definitive RT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005284","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:00:05Z","timestamp":1717765205000},"page":"e383-e389","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy"],"prefix":"10.1097","volume":"49","author":[{"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Faculty of Medicine, Baskent University, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petek","family":"Erpolat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gazi University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Sutera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Deek","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysenur","family":"Elmali","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek Tugce","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ummu Habibe","family":"Koken","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gazi University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melek","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","year":"2017","journal-title":"Eur Urol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"bib5-20250621","first-page":"djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.prro.2012.11.011","article-title":"Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival","volume":"3","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2014.01.008","article-title":"The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study","volume":"88","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.radonc.2019.05.016","article-title":"Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand radiation oncology genito-urinary group","volume":"140","year":"2019","journal-title":"Radiother Oncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/pros.24579","article-title":"PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET\/CT within a prospective study","volume":"83","year":"2023","journal-title":"Prostate"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"814","DOI":"10.21037\/tau.2018.08.04","article-title":"Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer","volume":"7","year":"2018","journal-title":"Transl Androl Urol"},{"key":"bib14-20250621","first-page":"13","article-title":"Oncologic imaging of the lymphatic system: current perspective with multi-modality imaging and new horizon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ctrv.2012.05.005","article-title":"Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm","volume":"38","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/pros.24558","article-title":"Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients","volume":"83","year":"2023","journal-title":"Prostate"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"20130617","DOI":"10.1259\/bjr.20130617","article-title":"Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy","volume":"87","year":"2014","journal-title":"Br J Radiol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2020.08.021","article-title":"Role of 68-Ga-PSMA-PET\/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients","volume":"151","year":"2020","journal-title":"Radiother Oncol"},{"key":"bib20-20250621","first-page":"1143","article-title":"The role of PSA in the radiotherapy of prostate cancer","volume":"10","year":"1996","journal-title":"Oncology (Williston Park)"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.1996.14.11.2893","article-title":"Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer","volume":"14","year":"1996","journal-title":"J Clin Oncol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31","volume":"61","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.crad.2015.12.001","article-title":"Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer","volume":"71","year":"2016","journal-title":"Clin Radiol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","year":"2008","journal-title":"Clin Radiol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"(68)Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of (68)Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/RLU.0000000000002691","article-title":"Integration of 68Ga-PSMA-PET\/CT in radiotherapy planning for prostate cancer patients","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.ijrobp.2012.08.036","article-title":"PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era","volume":"85","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.radonc.2008.10.004","article-title":"PSA response signatures\u2014a powerful new prognostic indicator after radiation for prostate cancer?","volume":"90","year":"2009","journal-title":"Radiother Oncol"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:03Z","timestamp":1750532463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005284"}},"subtitle":["Comparative Analysis of PSMA PET\/CT and Conventional Imaging"],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005284","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}